medical marijuana patient reviews
A comparison of medical marijuana patient reviews: our top-rated pick for consistency, plus the flower, vape, and edible options patients reorder most.
Real medical cannabis patient stories are first person accounts. They name a product, a dose, a schedule, and a result. They are not evidence that cannabis treats a disease. Use them to learn how state programs run and what side effects people report. Use trial data and FDA labels to judge whether a drug works.
A story with numbers tells you more than a story with opinions. Check for these items.
State health departments publish enrollment counts and the list of qualifying conditions. Those pages show how many patients a state has and which conditions it accepts. They do not report outcomes.
Clinical trial reports carry patient level detail under controlled conditions. The FDA has approved four drugs that contain cannabinoids: dronabinol (Marinol, Syndros), nabilone (Cesamet), and cannabidiol (Epidiolex). Epidiolex gained approval in June 2018 for two epilepsy syndromes, Lennox-Gastaut and Dravet, in patients age 2 and older. A 2020 approval added tuberous sclerosis complex.
medical cannabis testimonials for pain
Most stories you read online describe state-legal products with no FDA review. Label potency can differ from the content in the package. Ask for a batch lab report before you trust a potency claim.
NIH notes side effects that include impaired memory, altered judgment, and fast heartbeat. Heavy use of high-THC products links to cannabis use disorder and to psychosis in people with a family history. Driving after use raises crash risk. Federal law bars cannabis use for people in safety-sensitive jobs. VA health care does not fill cannabis prescriptions.
Cannabis remains a Schedule I substance under federal law. State programs set their own rules on possession limits, product types, and patient registration. A story from one state may describe products or doses that another state does not allow.